title: Controlled release of Rituximab from gold nanoparticles for phototherapy of malignant cells.
abstract: Releasing drug molecules at their targets with high spatial and temporal accuracy could aid numerous clinical applications which require low systemic damage and low side effects. Nano-carriers of drugs are an attractive solution for such task, allowing specific accumulation in tumors and gradual release of their payload. Here, we utilize gold nanospheres conjugated to Rituximab, an anti-CD20 monoclonal antibody-based drug, for carrying and releasing the drug upon irradiation of specifically tailored femtosecond laser pulses. The released anti-CD20 molecules retain their functionality and ability of triggering the complement-dependent cytotoxicity. This effect comes in addition to cell necrosis caused by the plasmonic nanometric shock waves emanating from the nanospheres and rupturing the plasma membranes. Main advantages of the presented technique include high spatial and temporal resolution, low toxicity and high repeatability and consistency due to the morphological stability of the nanospheres.
authors: Department of Biomedical Engineering, Technion-Israel Institute of Technology, Haifa 32000, Israel.
authors: Gili
authors: G
authors: Bisker
authors: Daniella
authors: D
authors: Yeheskely-Hayon
authors: Limor
authors: L
authors: Minai
authors: Dvir
authors: D
authors: Yelin
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage* / Q000737:chemistry; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000737:chemistry; D045744:Cell Line, Tumor; D003692:Delayed-Action Preparations / Q000008:administration & dosage* / Q000737:chemistry; D006046:Gold / Q000008:administration & dosage* / Q000737:chemistry; D006801:Humans; D007834:Lasers; D053768:Metal Nanoparticles / Q000008:administration & dosage / Q000737:chemistry; D054118:Nanospheres / Q000008:administration & dosage* / Q000737:chemistry; D009369:Neoplasms / Q000628:therapy; D010789:Phototherapy; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D000069283:Rituximab; D006046:Gold